Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
While EPI-002 (5–35 μM; 2–3 days) does not affect the survivability of PC3 human truck cadavers that do not express functional AR, it does activate AR in LNCaP cells [1]. In LNCaP cells, forskolin-induced transactivation of the ARN termination domain (NTD) is inhibited by ralantiten (10–35 μM; 4 hours) [1].
|
---|---|
ln Vivo |
In vitro, EPI-002 (100 mg/kg; administered twice daily for 28 days) suppresses and modifies the formation of VCaP tumors in mice [1].
|
Animal Protocol |
Animal/Disease Models: Male subcutaneoustumor NOD-SCID (severe combined immunodeficient) mouse Castrate
Doses: 100 mg/kg Administration Doses: 100 mg/kg: PO twice (two times) daily for 28 days Experimental Results: Inhibition of expression of AR splice variants castration resistance Growth of prostate cancer (CRPC) xenografts [1]. |
References |
[1]. Myung JK, et, al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013 Jul;123(7):2948-60.
[2]. Yang YC, et, al. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2016 Sep 1;22(17):4466-77. |
Molecular Formula |
C21H27CLO5
|
---|---|
Molecular Weight |
394.889086008072
|
CAS # |
1203490-23-6
|
Related CAS # |
Ralaniten triacetate;1637573-04-6
|
SMILES |
ClC[C@H](COC1C=CC(=CC=1)C(C)(C)C1C=CC(=CC=1)OC[C@@H](CO)O)O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~253.24 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.33 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5324 mL | 12.6618 mL | 25.3235 mL | |
5 mM | 0.5065 mL | 2.5324 mL | 5.0647 mL | |
10 mM | 0.2532 mL | 1.2662 mL | 2.5324 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.